ISDA

Entry Detail

PDB ID:

5QCK

Keywords:

Title:

FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2017-08-10

Release Date:

2017-11-08

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.64 Å

R-Value Free:

0.20

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 32 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Coagulation factor XI
Chain IDs:A
Chain Length:244
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P03951 Pfam ID:PF00089 EC:3.4.21.27

Ligand Molecules

BUV

EDO

SO4

Primary Citation

Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).

Pinto, D.J.P, Orwat, M.J, Smith, L.M, Quan, M.L, Lam, P.Y.S, Rossi, K.A, Apedo, A, Bozarth, J.M, Wu, Y, Zheng, J.J, Xin, B, Toussaint, N, Stetsko, P, Gudmundsson, O, Maxwell, B, Crain, E.J, Wong, P.C, Lou, Z, Harper, T.W, Chacko, S.A, Myers, J.E, Sheriff, S, Zhang, H, Hou, X, Mathur, A, Seiffert, D.A, Wexler, R.R, Luettgen, J.M, Ewing, W.R, Quan, M.L, Wong, P.C, Wang, C, Woerner, F, Smallheer, J.M, Barbera, F.A, Bozarth, J.M, Brown, R.L, Harpel, M.R, Luettgen, J.M, Morin, P.E, Peterson, T, Ramamurthy, V, Rendina, A.R, Rossi, K.A, Watson, C.A, Wei, A, Zhang, G, Seiffert, D, Wexler, R.R, Hangeland, J.J, Friends, T.J, Rossi, K.A, Smallheer, J.M, Wang, C, Sun, Z, Corte, J.R, Fang, T, Wong, P.C, Rendina, A.R, Barbera, F.A, Bozarth, J.M, Luettgen, J.M, Watson, C.A, Zhang, G, Wei, A, Ramamurthy, V, Morin, P.E, Bisacchi, G.S, Subramaniam, S, Arunachalam, P, Mathur, A, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Hangeland, J.J, Friends, T.J, Rendina, A.R, Luettgen, J.M, Bozarth, J.M, Barbera, F.A, Rossi, K.A, Wei, A, Ramamurthy, V, Morin, P.E, Seiffert, D.A, Wexler, R.R, Quan, M.L, Pinto, D.J, Smallheer, J.M, Corte, J.R, Austin, E.J, Wang, C, Fang, T, Smith, L.M, Rossi, K.A, Rendina, A.R, Bozarth, J.M, Zhang, G, Wei, A, Ramamurthy, V, Sheriff, S, Myers, J.E, Morin, P.E, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Hu, Z, Wong, P.C, Gilligan, P.J, Han, W, Pabbisetty, K.B, Bozarth, J.M, Crain, E.J, Harper, T, Luettgen, J.M, Myers, J.E, Ramamurthy, V, Rossi, K.A, Sheriff, S, Watson, C.A, Wei, A, Zheng, J.J, Seiffert, D.A, Wexler, R.R, Quan, M.L, Smith, L.M, Orwat, M.J, Hu, Z, Han, W, Wang, C, Rossi, K.A, Gilligan, P.J, Pabbisetty, K.B, Osuna, H, Corte, J.R, Rendina, A.R, Luettgen, J.M, Wong, P.C, Narayanan, R, Harper, T.W, Bozarth, J.M, Crain, E.J, Wei, A, Ramamurthy, V, Morin, P.E, Xin, B, Zheng, J, Seiffert, D.A, Quan, M.L, Lam, P.Y.S, Wexler, R.R, Pinto, D.J.P, Corte, J.R, Fang, T, Pinto, D.J, Orwat, M.J, Rendina, A.R, Luettgen, J.M, Rossi, K.A, Wei, A, Ramamurthy, V, Myers, J.E, Sheriff, S, Narayanan, R, Harper, T.W, Zheng, J.J, Li, Y.X, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Osuna, H, Pinto, D.J, Rossi, K.A, Myers, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Decicco, C.P, Wexler, R.R, Quan, M.L, Corte, J.R, Yang, W, Fang, T, Wang, Y, Osuna, H, Lai, A, Ewing, W.R, Rossi, K.A, Myers, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Lam, P.Y.S, Wang, C, Corte, J.R, Rossi, K.A, Bozarth, J.M, Wu, Y, Sheriff, S, Myers, J.E, Luettgen, J.M, Seiffert, D.A, Wexler, R.R, Quan, M.L.Show

J. Med. Chem. 60 9703 9723 (2017)

PMID: 29077405 DOI: 10.1021/acs.jmedchem.7b01171

Abstact

Factor XIa (FXIa) is a blood coagulation enzyme that is involved in the amplification of thrombin generation. Mounting evidence suggests that direct inhibition of FXIa can block pathologic thrombus formation while preserving normal hemostasis. Preclinical studies using a variety of approaches to reduce FXIa activity, including direct inhibitors of FXIa, have demonstrated good antithrombotic efficacy without increasing bleeding. On the basis of this potential, we targeted our efforts at identifying potent inhibitors of FXIa with a focus on discovering an acute antithrombotic agent for use in a hospital setting. Herein we describe the discovery of a potent FXIa clinical candidate, 55 (FXIa Ki = 0.7 nM), with excellent preclinical efficacy in thrombosis models and aqueous solubility suitable for intravenous administration. BMS-962212 is a reversible, direct, and highly selective small molecule inhibitor of FXIa.

Legend

Protein

Chemical

Disease

Primary Citation of related structures